USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$1 – $26
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your bumetanide prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Commonly reported side effects of bumetanide include: hypokalemia and hyperuricemia. See below for a comprehensive list of adverse effects.
Applies to bumetanide: oral tablet
Other dosage forms:
Oral route (Tablet)
Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs.
Along with its needed effects, bumetanide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking bumetanide:
Get emergency help immediately if any of the following symptoms of overdose occur while taking bumetanide:
Symptoms of overdose
Some side effects of bumetanide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to bumetanide: compounding powder, injectable solution, oral tablet
Metabolic side effects associated with bumetanide, as with other loop diuretics, occur in 7% to 20% of patients, and include hyponatremia, hypokalemia, hypochloremia, and hyperuricemia. These side effects may be more likely in patients with renal insufficiency. Glucose intolerance is reported in up to 14% of elderly patients. Hypokalemia may lead to increased renal tubular bicarbonate reabsorption, resulting in metabolic alkalosis.
Besides acting on the loop of Henle, bumetanide also inhibits phosphate reabsorption in the proximal tubule, resulting in phosphaturia. Since phosphorous is abundant in most diets, bumetanide-induced phosphaturia may not be significant except in malnourished patients, patients on life support, and patients with significant muscle weakness.
Calcium balance appears to remain neutral during treatment with a loop diuretic (i.e., furosemide, bumetanide). Although loop diuretics cause an increase in renal calcium excretion, this appears to be compensated for by a parathyroid-dependent increase in 1,25-dihydroxyvitamin D levels, which increases intestinal calcium absorption. Bone metabolism does not appear to be significantly affected by loop diuretics.
Musculoskeletal side effects have included muscle cramps in 1.1% and weakness in 0.2% of patients.
Renal insufficiency, manifested as a rise in serum creatinine and BUN, may occur in up to 7% of patients. It is usually due to extracellular fluid volume depletion and is readily reversible.
Cardiovascular side effects include hypotension in less than 2% of patients. Patients with a history of cardiac arrhythmias should be monitored closely because of the risk of hypokalemia.
Gastrointestinal side effects were reported in less than 2% of patients and included nausea, vomiting, loose stools, and constipation. There have been rare reports of hyperamylasemia and pancreatitis associated with bumetanide use.
Nervous system side effects, such as headache, dizziness, deafness, tinnitus, vertigo, and decreased hearing, are reported in less than 2% of patients. Encephalopathy after bumetanide administration is reported in patients with severe liver disease.
Severe hypersensitivity reactions such as Stevens-Johnson syndrome and recurrent urticaria have been reported in rare cases.
Hypersensitivity reactions are rare. Rash is reported in less than 1% of treated patients. Because cross-reactivity with furosemide is rare, bumetanide can be substituted at about a 1:40 dose ratio of bumetanide to furosemide in patients allergic to furosemide.
Dermatologic side effects have included pseudoporphyria, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Hematologic side effects are extremely rare. Cases of thrombocytopenia, mild anemia, and leukopenia have been reported.
July 6, 2020
July 6, 2020
June 25, 2020
June 23, 2020
June 22, 2020
June 18, 2020